For tirzepatide, that translates to approximately 25 to 34 days after your final dose
The secondary outcomes comprising cardiometabolic risk factors (including high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), body mass index (BMI), insulin sensitivity index adjusted for BMI (ISI), systolic blood pressure (SBP), diastolic blood pressure (DBP)) [33] and multiple-organ complications (liver diseases: metabolic dysfunction-associated steatohepatitis, liver fibrosis, fibrosis in MASLD, liver cirrhosis, hepatocellular carcinoma (HCC), hepatic failure
Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers
(ii) Beginning with the 2027 ASM performance year, for ASM participants, the complex patient scoring adjustment components are calculated as follows for the specific risk indicators: (A) Medical complex patient scoring adjustment component = 1.5 + 4 * associated HCC standardized score calculated with the average HCC risk score assigned to beneficiaries (under the HCC risk adjustment model established by CMS in accordance with section 1853(a)(1) of the Act) seen by the ASM participant